{"id":2717,"date":"2012-08-01T17:28:02","date_gmt":"2012-08-01T15:28:02","guid":{"rendered":"https:\/\/www.rcts.fr\/uncategorized\/neoadjuvant-bevacizumab-trastuzumab-and-chemotherapy-for-primary-inflammatory-her2-positive-breast-cancer-beverly-2-an-open-label-single-arm-phase-2-study"},"modified":"2020-04-07T16:10:19","modified_gmt":"2020-04-07T14:10:19","slug":"neoadjuvant-bevacizumab-trastuzumab-and-chemotherapy-for-primary-inflammatory-her2-positive-breast-cancer-beverly-2-an-open-label-single-arm-phase-2-study","status":"publish","type":"post","link":"https:\/\/www.rcts.fr\/en\/neoadjuvant-bevacizumab-trastuzumab-and-chemotherapy-for-primary-inflammatory-her2-positive-breast-cancer-beverly-2-an-open-label-single-arm-phase-2-study\/","title":{"rendered":"Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study\u00a0"},"content":{"rendered":"<p>Lancet Onco 2012 DOI:10.1016\/S1470- 2045(12)70049-9 &#8211; Consulter l&#8217;abstract<br \/>\nJean-Yves Pierga, Thierry Petit, Thierry Delozier, Jean-Marc Ferrero, Mario Campone, Joseph Gligorov, Florence Lerebours, Henri Roch\u00e9, Thomas Bachelot, Emmanuelle Charafe-Jauffret, Maria Pavlyuk, Sandrine Kraemer, Fran\u00e7ois-Cl\u00e9ment Bidard, Patrice Viens<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lancet Onco 2012 DOI:10.1016\/S1470- 2045(12)70049-9 &#8211; Consulter l&#8217;abstract Jean-Yves Pierga, Thierry Petit, Thierry Delozier, Jean-Marc Ferrero, Mario Campone, Joseph Gligorov, Florence Lerebours, Henri Roch\u00e9, Thomas Bachelot, Emmanuelle Charafe-Jauffret, Maria Pavlyuk, Sandrine Kraemer, Fran\u00e7ois-Cl\u00e9ment Bidard, Patrice Viens<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false},"categories":[63],"class_list":["post-2717","post","type-post","status-publish","format-standard","hentry","category-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study\u00a0 - RCTs<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"http:\/\/www.rcts.fr\/en\/neoadjuvant-bevacizumab-trastuzumab-and-chemotherapy-for-primary-inflammatory-her2-positive-breast-cancer-beverly-2-an-open-label-single-arm-phase-2-study\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study\u00a0 - RCTs\" \/>\n<meta property=\"og:description\" content=\"Lancet Onco 2012 DOI:10.1016\/S1470- 2045(12)70049-9 &#8211; Consulter l&#8217;abstract Jean-Yves Pierga, Thierry Petit, Thierry Delozier, Jean-Marc Ferrero, Mario Campone, Joseph Gligorov, Florence Lerebours, Henri Roch\u00e9, Thomas Bachelot, Emmanuelle Charafe-Jauffret, Maria Pavlyuk, Sandrine Kraemer, Fran\u00e7ois-Cl\u00e9ment Bidard, Patrice Viens\" \/>\n<meta property=\"og:url\" content=\"http:\/\/www.rcts.fr\/en\/neoadjuvant-bevacizumab-trastuzumab-and-chemotherapy-for-primary-inflammatory-her2-positive-breast-cancer-beverly-2-an-open-label-single-arm-phase-2-study\/\" \/>\n<meta property=\"og:site_name\" content=\"RCTs\" \/>\n<meta property=\"article:published_time\" content=\"2012-08-01T15:28:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-04-07T14:10:19+00:00\" \/>\n<meta name=\"author\" content=\"Didier Not\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Didier Not\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"http:\\\/\\\/www.rcts.fr\\\/en\\\/neoadjuvant-bevacizumab-trastuzumab-and-chemotherapy-for-primary-inflammatory-her2-positive-breast-cancer-beverly-2-an-open-label-single-arm-phase-2-study\\\/#article\",\"isPartOf\":{\"@id\":\"http:\\\/\\\/www.rcts.fr\\\/en\\\/neoadjuvant-bevacizumab-trastuzumab-and-chemotherapy-for-primary-inflammatory-her2-positive-breast-cancer-beverly-2-an-open-label-single-arm-phase-2-study\\\/\"},\"author\":{\"name\":\"Didier Not\",\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#\\\/schema\\\/person\\\/19ff6b0ca72b83f30ac0a23e6ce05dc5\"},\"headline\":\"Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study\u00a0\",\"datePublished\":\"2012-08-01T15:28:02+00:00\",\"dateModified\":\"2020-04-07T14:10:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"http:\\\/\\\/www.rcts.fr\\\/en\\\/neoadjuvant-bevacizumab-trastuzumab-and-chemotherapy-for-primary-inflammatory-her2-positive-breast-cancer-beverly-2-an-open-label-single-arm-phase-2-study\\\/\"},\"wordCount\":58,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#organization\"},\"articleSection\":[\"Oncology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"http:\\\/\\\/www.rcts.fr\\\/en\\\/neoadjuvant-bevacizumab-trastuzumab-and-chemotherapy-for-primary-inflammatory-her2-positive-breast-cancer-beverly-2-an-open-label-single-arm-phase-2-study\\\/\",\"url\":\"http:\\\/\\\/www.rcts.fr\\\/en\\\/neoadjuvant-bevacizumab-trastuzumab-and-chemotherapy-for-primary-inflammatory-her2-positive-breast-cancer-beverly-2-an-open-label-single-arm-phase-2-study\\\/\",\"name\":\"Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study\u00a0 - RCTs\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#website\"},\"datePublished\":\"2012-08-01T15:28:02+00:00\",\"dateModified\":\"2020-04-07T14:10:19+00:00\",\"breadcrumb\":{\"@id\":\"http:\\\/\\\/www.rcts.fr\\\/en\\\/neoadjuvant-bevacizumab-trastuzumab-and-chemotherapy-for-primary-inflammatory-her2-positive-breast-cancer-beverly-2-an-open-label-single-arm-phase-2-study\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"http:\\\/\\\/www.rcts.fr\\\/en\\\/neoadjuvant-bevacizumab-trastuzumab-and-chemotherapy-for-primary-inflammatory-her2-positive-breast-cancer-beverly-2-an-open-label-single-arm-phase-2-study\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"http:\\\/\\\/www.rcts.fr\\\/en\\\/neoadjuvant-bevacizumab-trastuzumab-and-chemotherapy-for-primary-inflammatory-her2-positive-breast-cancer-beverly-2-an-open-label-single-arm-phase-2-study\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.rcts.fr\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study\u00a0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#website\",\"url\":\"https:\\\/\\\/www.rcts.fr\\\/\",\"name\":\"RCTs\",\"description\":\"Description\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.rcts.fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#organization\",\"name\":\"RCTs\",\"url\":\"https:\\\/\\\/www.rcts.fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.rcts.fr\\\/wp-content\\\/uploads\\\/logo-blue.svg\",\"contentUrl\":\"https:\\\/\\\/www.rcts.fr\\\/wp-content\\\/uploads\\\/logo-blue.svg\",\"width\":163,\"height\":47,\"caption\":\"RCTs\"},\"image\":{\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#\\\/schema\\\/person\\\/19ff6b0ca72b83f30ac0a23e6ce05dc5\",\"name\":\"Didier Not\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/384084503863c2fae1497cd4aff02d7d7ec7ec0d357eb358655b55a5dd586850?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/384084503863c2fae1497cd4aff02d7d7ec7ec0d357eb358655b55a5dd586850?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/384084503863c2fae1497cd4aff02d7d7ec7ec0d357eb358655b55a5dd586850?s=96&d=mm&r=g\",\"caption\":\"Didier Not\"},\"url\":\"https:\\\/\\\/www.rcts.fr\\\/en\\\/author\\\/dnorcts-fr\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study\u00a0 - RCTs","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"http:\/\/www.rcts.fr\/en\/neoadjuvant-bevacizumab-trastuzumab-and-chemotherapy-for-primary-inflammatory-her2-positive-breast-cancer-beverly-2-an-open-label-single-arm-phase-2-study\/","og_locale":"en_US","og_type":"article","og_title":"Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study\u00a0 - RCTs","og_description":"Lancet Onco 2012 DOI:10.1016\/S1470- 2045(12)70049-9 &#8211; Consulter l&#8217;abstract Jean-Yves Pierga, Thierry Petit, Thierry Delozier, Jean-Marc Ferrero, Mario Campone, Joseph Gligorov, Florence Lerebours, Henri Roch\u00e9, Thomas Bachelot, Emmanuelle Charafe-Jauffret, Maria Pavlyuk, Sandrine Kraemer, Fran\u00e7ois-Cl\u00e9ment Bidard, Patrice Viens","og_url":"http:\/\/www.rcts.fr\/en\/neoadjuvant-bevacizumab-trastuzumab-and-chemotherapy-for-primary-inflammatory-her2-positive-breast-cancer-beverly-2-an-open-label-single-arm-phase-2-study\/","og_site_name":"RCTs","article_published_time":"2012-08-01T15:28:02+00:00","article_modified_time":"2020-04-07T14:10:19+00:00","author":"Didier Not","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Didier Not"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"http:\/\/www.rcts.fr\/en\/neoadjuvant-bevacizumab-trastuzumab-and-chemotherapy-for-primary-inflammatory-her2-positive-breast-cancer-beverly-2-an-open-label-single-arm-phase-2-study\/#article","isPartOf":{"@id":"http:\/\/www.rcts.fr\/en\/neoadjuvant-bevacizumab-trastuzumab-and-chemotherapy-for-primary-inflammatory-her2-positive-breast-cancer-beverly-2-an-open-label-single-arm-phase-2-study\/"},"author":{"name":"Didier Not","@id":"https:\/\/www.rcts.fr\/#\/schema\/person\/19ff6b0ca72b83f30ac0a23e6ce05dc5"},"headline":"Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study\u00a0","datePublished":"2012-08-01T15:28:02+00:00","dateModified":"2020-04-07T14:10:19+00:00","mainEntityOfPage":{"@id":"http:\/\/www.rcts.fr\/en\/neoadjuvant-bevacizumab-trastuzumab-and-chemotherapy-for-primary-inflammatory-her2-positive-breast-cancer-beverly-2-an-open-label-single-arm-phase-2-study\/"},"wordCount":58,"commentCount":0,"publisher":{"@id":"https:\/\/www.rcts.fr\/#organization"},"articleSection":["Oncology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"http:\/\/www.rcts.fr\/en\/neoadjuvant-bevacizumab-trastuzumab-and-chemotherapy-for-primary-inflammatory-her2-positive-breast-cancer-beverly-2-an-open-label-single-arm-phase-2-study\/","url":"http:\/\/www.rcts.fr\/en\/neoadjuvant-bevacizumab-trastuzumab-and-chemotherapy-for-primary-inflammatory-her2-positive-breast-cancer-beverly-2-an-open-label-single-arm-phase-2-study\/","name":"Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study\u00a0 - RCTs","isPartOf":{"@id":"https:\/\/www.rcts.fr\/#website"},"datePublished":"2012-08-01T15:28:02+00:00","dateModified":"2020-04-07T14:10:19+00:00","breadcrumb":{"@id":"http:\/\/www.rcts.fr\/en\/neoadjuvant-bevacizumab-trastuzumab-and-chemotherapy-for-primary-inflammatory-her2-positive-breast-cancer-beverly-2-an-open-label-single-arm-phase-2-study\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["http:\/\/www.rcts.fr\/en\/neoadjuvant-bevacizumab-trastuzumab-and-chemotherapy-for-primary-inflammatory-her2-positive-breast-cancer-beverly-2-an-open-label-single-arm-phase-2-study\/"]}]},{"@type":"BreadcrumbList","@id":"http:\/\/www.rcts.fr\/en\/neoadjuvant-bevacizumab-trastuzumab-and-chemotherapy-for-primary-inflammatory-her2-positive-breast-cancer-beverly-2-an-open-label-single-arm-phase-2-study\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.rcts.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study\u00a0"}]},{"@type":"WebSite","@id":"https:\/\/www.rcts.fr\/#website","url":"https:\/\/www.rcts.fr\/","name":"RCTs","description":"Description","publisher":{"@id":"https:\/\/www.rcts.fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.rcts.fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.rcts.fr\/#organization","name":"RCTs","url":"https:\/\/www.rcts.fr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.rcts.fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.rcts.fr\/wp-content\/uploads\/logo-blue.svg","contentUrl":"https:\/\/www.rcts.fr\/wp-content\/uploads\/logo-blue.svg","width":163,"height":47,"caption":"RCTs"},"image":{"@id":"https:\/\/www.rcts.fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.rcts.fr\/#\/schema\/person\/19ff6b0ca72b83f30ac0a23e6ce05dc5","name":"Didier Not","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/384084503863c2fae1497cd4aff02d7d7ec7ec0d357eb358655b55a5dd586850?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/384084503863c2fae1497cd4aff02d7d7ec7ec0d357eb358655b55a5dd586850?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/384084503863c2fae1497cd4aff02d7d7ec7ec0d357eb358655b55a5dd586850?s=96&d=mm&r=g","caption":"Didier Not"},"url":"https:\/\/www.rcts.fr\/en\/author\/dnorcts-fr\/"}]}},"_links":{"self":[{"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/posts\/2717","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/comments?post=2717"}],"version-history":[{"count":1,"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/posts\/2717\/revisions"}],"predecessor-version":[{"id":2718,"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/posts\/2717\/revisions\/2718"}],"wp:attachment":[{"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/media?parent=2717"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/categories?post=2717"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}